Effects of Anticoagulants on Experimental Models of Established Chronic Liver Diseases: A Systematic Review and Meta-Analysis
Joint Authors
Zhang, Rui
Huang, Xiaoquan
Jiang, Yingyi
Wang, Jian
Chen, Shiyao
Source
Canadian Journal of Gastroenterology and Hepatology
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-15, 15 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-12-12
Country of Publication
Egypt
No. of Pages
15
Main Subjects
Abstract EN
Objective.
The role of anticoagulants in chronic liver diseases is inconclusive.
A meta-analysis was thus undertaken to evaluate treatment-related survival and antifibrotic effects in animal models of chronic liver diseases.
Methods.
A systematic search of the literature took place (up to November 2020), screening for preclinical studies that evaluated anticoagulant effects in animal models of chronic liver diseases.
We assessed the quality of methods and the certainty of evidence.
Data on outcomes were extracted and pooled into random-effects models.
Results.
Sixteen studies proved eligible, each assessing anticoagulant use in animals with chronic liver diseases.
Generally, the pooled evidence demonstrated that the administration of anticoagulants is preventive against fibrogenesis, as indicated by METAVIR fibrosis scores (risk ratio = 0.66, 95% confidence interval: 0.47 to 0.94), portal pressure determinations (mean difference = −1.39, 95% confidence interval: −2.33 to −0.44), inflammatory activity (mean difference = −169.69, 95% confidence interval: −257.64 to −81.74), and indices of hepatic injury, specifically alanine aminotransferase (mean difference = −82.7, 95% confidence interval: −107.36 to −58.04), aspartate aminotransferase (mean difference = −186.12, 95% confidence interval: −254.90 to −117.33), albumin (mean difference = 0.59, 95% confidence interval: 0.16 to 1.01), and total bilirubin (mean difference = −0.96, 95% confidence interval: −1.46 to −0.46), and it had no impact on animal survival (risk ratio = 1.03, 95% confidence interval: 0.94 to 1.13).
Conclusions.
Our assessments indicate that in animal models of chronic liver diseases, anticoagulants may alleviate the degree of fibrosis evaluated by the METAVIR score system, portal pressure, inflammatory activity, and serum indices of hepatocellular injury, without impacting survival.
High-quality experimental studies are still required.
American Psychological Association (APA)
Zhang, Rui& Huang, Xiaoquan& Jiang, Yingyi& Wang, Jian& Chen, Shiyao. 2020. Effects of Anticoagulants on Experimental Models of Established Chronic Liver Diseases: A Systematic Review and Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology،Vol. 2020, no. 2020, pp.1-15.
https://search.emarefa.net/detail/BIM-1139073
Modern Language Association (MLA)
Zhang, Rui…[et al.]. Effects of Anticoagulants on Experimental Models of Established Chronic Liver Diseases: A Systematic Review and Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology No. 2020 (2020), pp.1-15.
https://search.emarefa.net/detail/BIM-1139073
American Medical Association (AMA)
Zhang, Rui& Huang, Xiaoquan& Jiang, Yingyi& Wang, Jian& Chen, Shiyao. Effects of Anticoagulants on Experimental Models of Established Chronic Liver Diseases: A Systematic Review and Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology. 2020. Vol. 2020, no. 2020, pp.1-15.
https://search.emarefa.net/detail/BIM-1139073
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1139073